home
01

Elevar

Founded in 2005, Elevar Therapeutics specializes in clinical development of promising therapies for unmet medical needs in cancer. Elevar Therapeutics is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.

Business Area

Rivoceranib

Rivoceranib is a selective potent inhibitor of vascular endothelial growth factor receptor-2 (known as VEGFR2) which mediates the primary pathway for tumor-mediated angiogenesis. Rivoceranib is a low-molecular inhibitor that is highly regarded as the best-in-class drug due to its high VEGRF-2 selectivity and fewer side effects.

Apealea®

Apealea® is a cancer medicine used to treat women with cancer of the ovary or surrounding structures (the fallopian tube that connects the ovary to the womb, or the peritoneum, the membrane that lines the abdomen).Apealea® is given along with a platinum-based medicine, carboplatin, to patients whose disease responds to platinum-based cancer medicines and has come back after initial treatment. Apealea® contains the active substance paclitaxel.

Company information
HQ
address

2825 E Cottonwood Pkwy Suite 180,Salt Lake City, UT 84121 U.S.A.

Tel

+1-801-303-7440


Fax

+1-801-303-7455

SFO Office
address

400 Oyster Point Blvd, Suite 214, South San Francisco, CA 94080 U.S.A.


Home

www.elevartherapeutics.com

E-mail

info@elevartherapeutics.com

HLB
GROUP
LIST
02

Immunomic
Therapeutics

Immunomic Therapeutics (ITI) is a U.S bio company founded in 2006 with more than seven pipeline assets that represent highly scalable product opportunities.
ITI has experience in exclusive licensing technology agreements and collaborations with many US leading academic institutions. ITI's nucleic acid vaccines have the potential to utilize the body's natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE at the crossroads of immunotherapies in several illnesses, including cancer, allergy and infectious diseases.

Business Area

UNITE (the next-generation vaccine platform)

UNITE stands for 'Universal Intracellular Targeted Expression'. UNITE is a powerful next-generation immunotherapy platform technology that targets specific antigens to lysosomes to increase antigen presentation and enhance cytotoxic T cell function. This platform is a highly scalable platform that can be applied to cancer and allergies.

Allergy Treatment

Allergy treatment technology using the UNITE technology is a proven technology licensed out to Japan's Astellas Pharmaceuticals in 2015 and is currently undergoing clinical trials for peanut and pollen allergy. It is expected to receive royalties in the future.

Glioblastoma Treatment

Glioblastoma has not been approved for new drugs in the past 20 years. IT's glioblastoma drug substance has a five-year survival rate of about seven times higher than existing drugs, and the median overall survival rate (OS) is over 40 months.

Company information
Headquarters & Lab
address

15010 Broschart Road Suite 250 Rockville, MD 20850

Tel

+1-301-968-3501

Home

www.immunomix.com

E-mail

info@immunomix.com

03

HLB LifeScience
Co., Ltd. Bio Div.

HLB LifeScience leaps forward as a global pharmaceutical company based on the discovery of first-in-class / best-in-class innovative new drugs and a differentiated new drug development network based on unmet need analysis.

Business Area

Domestic development of Rivoceranib

The bio business division of HLBLS is currently developing ‘Best-in-Class’ targeted-anticancer drug Rivoceranib(Apatinib) for marketing approval in Korea. HLBLS plans to maximize the versatility of Rivoceranib by expanding research in various cancer areas (stomach cancer, liver cancer, colon cancer etc.), non-cancer areas (age-related macular degeneration and dry eye disease) and animal cancers.

Seclidemstat: biomarker based solid tumor drug development

Seclidemstat normalizes tumor-related gene expressions that suppress proliferation and metastasis of cancer cells. It regulates lysine-specific histone demethylase 1A(LSD-1) that is over-activated in various tumor cells. It is a first-in-class epigenetic anticancer drug with a new promising MOA.

Tegavivint: novel Wnt/β-cat signal pathway based anticancer drug

Tegavivint is a novel drug that inhibits the progression of cancer by regulating the terminal signal transduction of Wnt/β-catenin pathway by blocking interplay between the over-generated β-catenin and TBL-1 protein within cancer cells. A successful Wnt/β-catenin pathway was previously unattainable due to repeated difficulties in controlling the MOA. However, Tegavivint presents a new paradigm as an innovative anticancer drug working in the Wnt/β-catenin signaling pathway.

Company information
HQ
address

8F, 51-9, Dongtancheomdansaneop 1-ro, Hwaseong-si, Gyeonggi-do, Republic of Korea

Tel

+82-2-2627-6748


Fax

+82-2-2627-6702

Seoul Office
address

(06193) 420, Teheran-ro, Mayple Tower 15f, Gangnam-gu, Seoul, Republic of Korea

Tel

+82-2-2627-6700


Fax

+82-2-2627-6703

Home

www.hlb-ls.com

E-mail

hlbls@hlb-ls.com

04

HLBCELL Co., Ltd.

Since 1998, HLB Cell (formerly Life Liver) has been dedicated to specialized stem cell research and tissue engineering research, including artificial liver therapies. We have differentiated pipelines such as artificial liver therapies, stem cell therapies, and surgical hemostatic agents.

Business Area

Bio Artificial Liver

Lifeliver™ is a cell therapy for prolonging the golden time of patients with acute liver failure waiting for liver transplantation.

Stem Cell Therapy

It is a stem cell therapeutic that can be applied to liver disease (urea dystrophy, nonalcoholic steatohepatitis, etc.) and soft tissue disease by applying mass culture technology to new stem cells derived from human body.

Biodegradable Medical Adhesive · Sealant

It is a powder-type product that can be used during surgery as well as various external bleedings.

Company information
HQ
address

3F , 2776, Yonggu-daero, Suji-gu, Yongin-si, Gyeonggi-do

Tel

+82-31-709-8578


Fax

+82-31-701-8579

Main Laboratory
address

8F, 51-9, Dongtancheomdansaneop 1-ro, Hwaseong-si, Gyeonggi-do, Republic of Korea

Home

www.lifeliver.co.kr

E-mail

lifeliver@lifeliver.co.kr

05

Hwajin Medical
Co., Ltd.

Established in 1993, Hwajin Medical has become a specialized medical device manufacturer. The main products include disposable syringes, disposable needles, and filter syringes. We realize customer satisfaction and contributes to national health through continuous quality improvement efforts and R&D.

Major Products
Disposable syringe
Disposable needle
Filter syringe
Certification Status
Delivery Performance
Company information
HQ
address

20, Seongsimwon-gil, Seongnam-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do

Tel

+82-41-554-6181


Fax

+82-41-554-7178

Home

www.hwajinmedical.com

E-mail

hwajin@hwajinmedical.com

07

Shinhwa Advance
Co., Ltd.

As the leading distribution company in Korea that leads the online and offline pharmaceutical distribution market, we deliver to Ajou University Hospital, Cha Hospital (Seoul, Bundang) and national and public hospitals.

Business Area

With top domestic pharmaceutical companies such as Yuhan, Dong-A, Jeil, Daewoong, Hanmi, Chong Kun-dang, JW Middle School, Ildong, Boryeong, SK, CJ, Pfizer, gsk, Novartis, Sanofi-Aventis, MSD, Astra Zeneca, Boehringer-ingelheim, we are conducting business activities through direct transactions with leading foreign pharmaceutical companies such as BMS.

Delivery Performance
Company information
HQ
address

150-858 191, Daebangcheon-ro, Yeongdeungpo-gu, Seoul (2nd floor of Shinhwa Building)

Tel

+82-2-834-7971


Fax

+82-2-834-7938

E-mail

shparm7@hanmail.net